DBV Technologies Raises €6M in Series B Financing
By James Etheridge
Wednesday, January 28, 2009
BioWorld International Correspondent
PARIS - DBV Technologies, which specializes in the diagnosis and treatment of allergies, completed a series B financing in which it raised €6 million (US$7.9 million) from one new and one existing investor.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.